Fig 1: Pre-symptomatic VX-765 treatment normalizes IL-1ß but does not affect inflammasome and caspase expression.a Il-1ß and Il-18 mRNA levels in the hippocampus at 4-week (n = 4 WT + veh, 3 J20 + veh, 3 J20 + VX mice), 12-week (n = 4 WT + veh, 3 J20 + veh, 3 J20 + VX mice) and 20-week (n = 4 mice per group) WO. b IL-1ß western blots showing hippocampal inactive (pro-) and active (?) IL-1ß per group at 4- and 20-week WO. c–h IL-1ß western blot quantification in the hippocampus and cortex comparing (c, f) pro IL-1ß, (d, g) ?IL-1ß and (e, h) total IL-1ß at (c–e) 4-week WO, and (f–h) 20-week WO [cortical ?IL-1ß 20-week WO F(2,7) = 12.03, p = 0.0054, ANOVA, Dunnett’s post hoc compared to WT + vehicle]. In (c–h), n = 7 mice per group in 4-week WO hippocampus; n = 8 WT + veh, 7 J20 + veh, 7 J20 + VX mice in 20-week WO hippocampus; n = 3 per group in 4- and 20-week WO cortex. i ELISA measuring total hippocampal and cortical IL-1ß levels at 4-week (n = 7 WT + veh, 7 J20 + veh, 8 J20 + VX mice), 12-week (n = 8 WT + veh, 6 J20 + veh, 7 J20 + VX mice) and 20-week (n = 8 WT + veh, 7 J20 + veh, 7 J20 + VX mice) WO. j Casp1 and Casp6 mRNA levels in the hippocampus at 4-week (n = 4 WT + veh, 3 J20 + veh, 3 J20 + VX mice), 12- (n = 4 WT + veh, n J20 + veh, 3 J20 + VX mice) and 20-week (n = 4 mice per group) WO. Data represents mean and s.e.m. **p < 0.01.